70
Participants
Start Date
January 31, 2012
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
Axitinib
5-mg tablets PO BID
Bevacizumab
5 mg/kg Days 1 and 15; IV
5-Fluorouracil
400 mg/m2 Days 1 and 15; IV
5-Fluorouracil
2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
Leucovorin
400 mg/m2 Days 1 and 15; IV
Oxaliplatin
85 mg/m2 Days 1 and 15; IV
Northeast Georgia Medical Center, Gainesville
Woodlands Medical Specialists, Pensacola
Florida Cancer Specialists-North, St. Petersburg
Florida Cancer Specialists-South, Fort Myers
Tennessee Oncology, Nashville
Oncology Hematology of SW Indiana, Newburgh
Hope Cancer Center, Terre Haute
Grand Rapids Oncology Program, Grand Rapids
Nebraska Methodist Hospital, Omaha
NEA Baptist Clinic, Jonesboro
Texas Health Physician Group, Dallas
Atlantic Health System, Summit
Collaborators (1)
Pfizer
INDUSTRY
SCRI Development Innovations, LLC
OTHER